Bhavana Pothuri

Bhavana Pothuri is a clinical investigator specializing in systemic therapy for gynecologic malignancies including cervical cancer. She has participated in landmark trials including KEYNOTE-826, which established pembrolizumab plus chemotherapy as standard of care for PD-L1 positive advanced cervical cancer. She investigates novel agents including tisotumab vedotin and PARP inhibitors in gynecologic cancers. Her research bridges biomarker-driven patient selection with clinical outcomes in cervical, ovarian, and uterine cancers. She is an active contributor to the GOG Partners clinical trials consortium.